Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mutations in EPHB4 cause human venous valve aplasia
Oliver Lyons, James Walker, Christopher Seet, Mohammed Ikram, Adam Kuchta, Andrew Arnold, Magda Hernández-Vásquez, Maike Frye, Gema Vizcay-Barrena, Roland A. Fleck, Ashish S. Patel, Soundrie Padayachee, Peter Mortimer, Steve Jeffery, Siren Berland, Sahar Mansour, Pia Ostergaard, Taija Makinen, Bijan Modarai, Prakash Saha, Alberto Smith
Oliver Lyons, James Walker, Christopher Seet, Mohammed Ikram, Adam Kuchta, Andrew Arnold, Magda Hernández-Vásquez, Maike Frye, Gema Vizcay-Barrena, Roland A. Fleck, Ashish S. Patel, Soundrie Padayachee, Peter Mortimer, Steve Jeffery, Siren Berland, Sahar Mansour, Pia Ostergaard, Taija Makinen, Bijan Modarai, Prakash Saha, Alberto Smith
View: Text | PDF
Research Article Angiogenesis Development

Mutations in EPHB4 cause human venous valve aplasia

  • Text
  • PDF
Abstract

Venous valve (VV) failure causes chronic venous insufficiency, but the molecular regulation of valve development is poorly understood. A primary lymphatic anomaly, caused by mutations in the receptor tyrosine kinase EPHB4, was recently described, with these patients also presenting with venous insufficiency. Whether the venous anomalies are the result of an effect on VVs is not known. VV formation requires complex “organization” of valve-forming endothelial cells, including their reorientation perpendicular to the direction of blood flow. Using quantitative ultrasound, we identified substantial VV aplasia and deep venous reflux in patients with mutations in EPHB4. We used a GFP reporter in mice to study expression of its ligand, ephrinB2, and analyzed developmental phenotypes after conditional deletion of floxed Ephb4 and Efnb2 alleles. EphB4 and ephrinB2 expression patterns were dynamically regulated around organizing valve-forming cells. Efnb2 deletion disrupted the normal endothelial expression patterns of the gap junction proteins connexin37 and connexin43 (both required for normal valve development) around reorientating valve-forming cells and produced deficient valve-forming cell elongation, reorientation, polarity, and proliferation. Ephb4 was also required for valve-forming cell organization and subsequent growth of the valve leaflets. These results uncover a potentially novel cause of primary human VV aplasia.

Authors

Oliver Lyons, James Walker, Christopher Seet, Mohammed Ikram, Adam Kuchta, Andrew Arnold, Magda Hernández-Vásquez, Maike Frye, Gema Vizcay-Barrena, Roland A. Fleck, Ashish S. Patel, Soundrie Padayachee, Peter Mortimer, Steve Jeffery, Siren Berland, Sahar Mansour, Pia Ostergaard, Taija Makinen, Bijan Modarai, Prakash Saha, Alberto Smith

×

Figure 7

Efnb2 deletion disrupts gap junction protein expression pattern and proliferation.

Options: View larger image (or click on image) Download as PowerPoint

Efnb2 deletion disrupts gap junction protein expression pattern and pro...
(A) Localization of PECAM1 (blue), and either Cx37 or Cx43, as indicated (magenta) around VFCs on P0 in heterozygous Efnb2GFP (green) mice. As expected, on P0 Cx37 was localized to Efnb2GFP-expressing VFCs, primarily forming large gap junction plaques (examples indicated between arrowheads) and Cx43 was localized to endothelium upstream of these VFCs (region to the left of the arrowheads). Smaller plaques are also identifiable. (B) Localization of PECAM1 (blue), Prox1 (red), and either Cx37 or Cx43, as indicated (green), after homozygous deletion of Efnb2. The tightly regulated expression pattern of Cx37 was disrupted, with expression over a wider area (arrowheads) and the typical appearance of larger plaques was lost. The expression pattern of Cx43 was also disrupted and no longer confined to upstream of VFCs (arrowheads; P < 0.05, χ2 test of the proportion of VVs showing normal [confined] vs. disrupted expression pattern, n ≥ 6 VV per group). (C and D) The proportion of proliferating VFCs was assessed by colocalization of Prox1 and Ki67 (arrowheads). Ki67+ VFCs were easily identified in littermate controls, but far fewer proliferating VFCs were identifiable after homozygous Efnb2 deletion. The inferior region of the vein is shown; ****P < 0.00005, unpaired 2-tailed t test, n ≥ 6 VV per group, data are shown as mean ± SEM). Scale bars in A–C: 20 μm. VFCs, valve-forming cells; VVs, venous valves; P0, postnatal day 0.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts